An unusual cause of graft loss in pediatric liver transplant recipient-Fasciola hepatica.
Animals
Child
Cholangitis
/ drug therapy
Contrast Media
End Stage Liver Disease
/ diagnostic imaging
Fasciola hepatica
Fascioliasis
/ complications
Female
Graft Rejection
/ parasitology
Humans
Immunosuppression Therapy
Immunosuppressive Agents
/ therapeutic use
India
Liver Transplantation
Morocco
Mycophenolic Acid
/ therapeutic use
Stem Cell Transplantation
Tacrolimus
/ therapeutic use
Tomography, X-Ray Computed
Fasciola hepatica
graft loss
liver transplantation
parasitic infection
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
07
12
2018
revised:
26
04
2019
accepted:
23
05
2019
pubmed:
27
6
2019
medline:
14
7
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
Fascioliasis is caused by the trematode liver fluke Fasciola hepatica. Humans are accidental hosts getting infected after ingesting contaminated plants or water. 90 million people in 75 nations are at risk of infection with F hepatica. Immunosuppressed patients are higher risk of acquiring infection and may present with atypical manifestations. Patients can present with hepatic involvement, biliary features or a combination of both. Confirmation of the diagnosis is by demonstration of live parasites or eggs in bile or feces, serology (immunoelectrophoresis, indirect immunofluorescence, indirect hemagglutination), ELISA, typical imaging findings or a combination of any of the above. The drug of choice for treatment is triclabendazole. Fascioliasis should always be considered as a possibility in post-LT patients with findings of hepatobiliary disorder from endemic areas. Unfamiliarity with this infection in non-endemic areas often eludes prompt diagnosis thereby increasing the morbidity. We report the first case of fascioliasis in a pediatric liver transplant recipient leading to graft loss and mortality.
Substances chimiques
Contrast Media
0
Immunosuppressive Agents
0
Mycophenolic Acid
HU9DX48N0T
Tacrolimus
WM0HAQ4WNM
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13521Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis. 2007;44(6):857-866.
Alatoom A, Cavuoti D, Southern P, Gander R. Fasciola hepatica infection in the United States. Lab Med. 2008;39(7):425-428.
Mas-Coma MS, Esteban JG, Bargues MD. Epidemiology of human fascioliasis: a review and proposed new classification. Bull World Health Organ. 1999;77(4):340-346.
Aksoy DY, Kerimoglu U, Oto A, et al. Infection with Fasciola hepatica. Clin Microbiol Infect. 2005;11(11):859-861.
Kaya M, Beştaş R, Çetin S. Clinical presentation and management of Fasciola hepatica infection: single-center experience. World J Gastroenterol. 2011;17(44):4899-4904.
Parasites (2019, January 14).https://www.cdc.gov/parasites/fasciola/health_professionals/index.htm. Accessed April 2, 2019.